Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Alexion reports that the FDA has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for...
The BIO International Convention, one of the world’s largest forums for the biotech sector, welcomed a record number of attendees to Philadelphia earlier this month. Connecticut was center...
BioCT is proud to work with community members of all sizes that are committed to growing Connecticut’s bioscience industry and improving patient’s lives and public...
MapKure intends to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations,...
Artizan Biosciences, a biotechnology company focused on curing inflammatory bowel disease by targeting bacteria that inhabit the gastrointestinal system, is returning to its New Haven...
Pfizer’s Groton site has had a hand in the discovery and development of such medicines as Zoloft and Zithromax and, more recently, Xalkori and Xeljanz....
Achillion Pharmaceuticals reports that Brian Di Donato, Chief Financial Officer, and Steven Zelenkofske, D.O., Chief Medical Officer, will present at the JMP Securities Life Sciences...
Artizan Biosciences has announced corporate and financial updates: Artizan has completed its Series A funding, bringing the total raised to date to $12 million. Paul...
A team of University of Connecticut researchers has received a $2.8 million grant from the National Institutes of Health for a five-year project studying how...
New Haven and Danbury are among the top 50 cities in the U.S. with populations of less than a million, according to a new study...